{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T10:39:29Z","timestamp":1778323169244,"version":"3.51.4"},"reference-count":138,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Physiology & Behavior"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.physbeh.2011.05.033","type":"journal-article","created":{"date-parts":[[2011,6,25]],"date-time":"2011-06-25T09:01:01Z","timestamp":1308992461000},"page":"590-598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism"],"prefix":"10.1016","volume":"104","author":[{"given":"Karen L.","family":"Teff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangwon F.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.physbeh.2011.05.033_bb0005","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2174\/1389450043490514","article-title":"Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics","volume":"5","author":"Baptista","year":"2004","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.physbeh.2011.05.033_bb0010","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.157.6.975","article-title":"Clozapine, diabetes mellitus, weight gain, and lipid abnomalities: a five year naturalistic study","volume":"157","author":"Henderson","year":"2000","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.physbeh.2011.05.033_bb0015","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archpsyc.59.4.337","article-title":"Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia","volume":"59","author":"Newcomer","year":"2002","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"10.1016\/j.physbeh.2011.05.033_bb0020","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/ebmh.9.3.72","article-title":"Olanzapine is associated with more rapid weight gain than haloperidol in people with first episode psychosis","volume":"9","author":"Lambert","year":"2006","journal-title":"Evid Based Ment Health"},{"issue":"1","key":"10.1016\/j.physbeh.2011.05.033_bb0025","first-page":"1","article-title":"Relative risk of glucose elevation during antipsychotic exposure in a Veterans Administration population","volume":"22","author":"Duncan","year":"2007","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.physbeh.2011.05.033_bb0030","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1176\/appi.ajp.160.2.290","article-title":"Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics","volume":"160","author":"Lindenmayer","year":"2003","journal-title":"Am J Psychiatry"},{"issue":"6","key":"10.1016\/j.physbeh.2011.05.033_bb0035","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/01.yic.0000224786.75664.3b","article-title":"Early changes of plasma lipids during treatment with atypical antipsychotics","volume":"21","author":"Rettenbacher","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.physbeh.2011.05.033_bb0040","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.jcp.0000227705.56870.06","article-title":"Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics","volume":"26","author":"Hardy","year":"2006","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.physbeh.2011.05.033_bb0045","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.schres.2005.05.001","article-title":"Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan","volume":"80","author":"Huang","year":"2005","journal-title":"Schizophr Res"},{"key":"10.1016\/j.physbeh.2011.05.033_bb0050","doi-asserted-by":"crossref","unstructured":"Ried LD, Renner BT, McConkey JR, Bengtson MA, Lopez LM. Increased cardiovascular risk with second-generation antipsychotic agent switches. J Am Pharm Assoc (2003) 2006; 46(4):491\u2013498.","DOI":"10.1331\/154434506778073574"},{"issue":"12","key":"10.1016\/j.physbeh.2011.05.033_bb0055","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.biopsych.2006.03.014","article-title":"Serum free fatty acids and glucose metabolism, insulin resistance in schizophrenia with chronic antipsychotics","volume":"60","author":"Wang","year":"2006","journal-title":"Biol Psychiatry"},{"issue":"7 Suppl. 7","key":"10.1016\/j.physbeh.2011.05.033_bb0060","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1017\/S1092852900026663","article-title":"Metabolic findings from the CATIE trial and their relation to tolerability","volume":"11","author":"Nasrallah","year":"2006","journal-title":"CNS Spectr"},{"issue":"Suppl. 1","key":"10.1016\/j.physbeh.2011.05.033_bb0065","first-page":"20","article-title":"Metabolic considerations in the use of antipsychotic medications: a review of recent evidence","volume":"68","author":"Newcomer","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.physbeh.2011.05.033_bb0070","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2337\/diacare.29.01.06.dc05-1320","article-title":"Metabolic syndrome: risk factor distribution and 18-year mortality in the multiple risk factor intervention trial","volume":"29","author":"Eberly","year":"2006","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.physbeh.2011.05.033_bb0075","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.schres.2005.08.010","article-title":"A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls","volume":"80","author":"Goff","year":"2005","journal-title":"Schizophr Res"},{"issue":"4","key":"10.1016\/j.physbeh.2011.05.033_bb0080","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/sj.npp.1301142","article-title":"Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis","volume":"32","author":"Vestri","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.physbeh.2011.05.033_bb0085","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.phrs.2007.05.007","article-title":"Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells","volume":"56","author":"Yang","year":"2007","journal-title":"Pharmacol Res"},{"issue":"6","key":"10.1016\/j.physbeh.2011.05.033_bb0090","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/sj.ijo.0802928","article-title":"Antipsychotic drug-induced weight gain: development of an animal model","volume":"29","author":"Cope","year":"2005","journal-title":"Int J Obes (Lond)"},{"issue":"4","key":"10.1016\/j.physbeh.2011.05.033_bb0095","doi-asserted-by":"crossref","first-page":"E624","DOI":"10.1152\/ajpendo.00502.2010","article-title":"Atypical antipsychotic drugs perturb AMPK-dependent regulation of hepatic lipid metabolism","volume":"300","author":"Oh","year":"2011","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"16","key":"10.1016\/j.physbeh.2011.05.033_bb0100","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.physbeh.2011.05.033_bb0105","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/01.jcp.0000219916.88810.1c","article-title":"Early predictors of substantial weight gain in bipolar patients treated with olanzapine","volume":"26","author":"Lipkovich","year":"2006","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"10.1016\/j.physbeh.2011.05.033_bb0110","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1586\/14737175.4.5.759","article-title":"Use of olanzapine in the treatment of bipolar I disorder","volume":"4","author":"Lieberman","year":"2004","journal-title":"Expert Rev Neurother"},{"issue":"2","key":"10.1016\/j.physbeh.2011.05.033_bb0115","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/00003495-199753020-00007","article-title":"Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses","volume":"53","author":"Fulton","year":"1997","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.physbeh.2011.05.033_bb0120","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/00004714-199908000-00006","article-title":"Weight gain: side effect of atypical neuroleptics?","volume":"19","author":"Wetterling","year":"1999","journal-title":"J Clin Psychopharmacol"},{"issue":"11","key":"10.1016\/j.physbeh.2011.05.033_bb0125","doi-asserted-by":"crossref","first-page":"783","DOI":"10.4088\/JCP.v60n1112","article-title":"Different influences of classical antipsychotics and clozapine on glucose\u2013insulin homeostasis in patients with schizophrenia or related psychoses","volume":"60","author":"Melkersson","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.physbeh.2011.05.033_bb0130","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.physbeh.2011.05.033_bb0135","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.schres.2005.07.015","article-title":"The clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome","volume":"80","author":"Meyer","year":"2005","journal-title":"Schizophr Res"},{"issue":"1\u20133","key":"10.1016\/j.physbeh.2011.05.033_bb0140","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.schres.2008.09.025","article-title":"Weight effects associated with antipsychotics: a comprehensive database analysis","volume":"110","author":"Parsons","year":"2009","journal-title":"Schizophr Res"},{"issue":"8","key":"10.1016\/j.physbeh.2011.05.033_bb0145","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/oby.2010.6","article-title":"Increased food intake and energy expenditure following administration of olanzapine to healthy men","volume":"18","author":"Fountaine","year":"2010","journal-title":"Obesity (Silver Spring)"},{"issue":"8","key":"10.1016\/j.physbeh.2011.05.033_bb0150","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1038\/oby.2008.277","article-title":"Adiposity and eating behaviors in patients under second generation antipsychotics","volume":"16","author":"Blouin","year":"2008","journal-title":"Obesity (Silver Spring)"},{"issue":"5","key":"10.1016\/j.physbeh.2011.05.033_bb0155","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/01.jcp.0000177549.36585.29","article-title":"A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors","volume":"25","author":"Roerig","year":"2005","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.physbeh.2011.05.033_bb0160","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/jcp.0b013e31815a8872","article-title":"Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study","volume":"27","author":"Kluge","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.physbeh.2011.05.033_bb0165","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-244X-10-72","article-title":"The potential role of appetite in predicting weight changes during treatment with olanzapine","volume":"10","author":"Case","year":"2010","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.physbeh.2011.05.033_bb0170","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0022-3999(85)90010-8","article-title":"The three factor eating questionnaire to measure dietary restraint, disinhibition and hunger","volume":"29","author":"Stunkard","year":"1985","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.physbeh.2011.05.033_bb0175","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-244X-9-12","article-title":"Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents: a post-hoc analysis","volume":"9","author":"Stauffer","year":"2009","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.physbeh.2011.05.033_bb0180","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0091-3057(03)00042-X","article-title":"Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human","volume":"75","author":"Pouzet","year":"2003","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"10.1016\/j.physbeh.2011.05.033_bb0185","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0091-3057(03)00079-0","article-title":"Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake","volume":"75","author":"Dwyer","year":"2003","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"10.1016\/j.physbeh.2011.05.033_bb0190","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s00213-003-1553-4","article-title":"Effects of clozapine on behavioral and metabolic traits relevant for schizophrenia in two mouse strains","volume":"171","author":"Zarate","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"10.1016\/j.physbeh.2011.05.033_bb0195","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0278-5846(01)00266-4","article-title":"Studies on modulation of feeding behavior by atypical antipsychotics in female mice","volume":"26","author":"Kaur","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"10.1016\/j.physbeh.2011.05.033_bb0200","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00213-006-0368-5","article-title":"Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects","volume":"186","author":"Coccurello","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"10.1016\/j.physbeh.2011.05.033_bb0205","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00213-008-1415-1","article-title":"Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine","volume":"203","author":"Davoodi","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"10.1016\/j.physbeh.2011.05.033_bb0210","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/0269881106069637","article-title":"Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities","volume":"21","author":"Cooper","year":"2007","journal-title":"J Psychopharmacol"},{"issue":"2","key":"10.1016\/j.physbeh.2011.05.033_bb0215","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.pnpbp.2007.09.012","article-title":"Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain","volume":"32","author":"Cooper","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"10.1016\/j.physbeh.2011.05.033_bb0220","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejphar.2007.11.078","article-title":"Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution","volume":"585","author":"van der Zwaal","year":"2008","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.physbeh.2011.05.033_bb0225","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/0269881104040253","article-title":"Management of diabetes mellitus occurring during treatment with olanzapine: report of six cases and clinical implications","volume":"18","author":"Ashim","year":"2004","journal-title":"J Psychopharmacol"},{"issue":"5 Suppl. 1","key":"10.1016\/j.physbeh.2011.05.033_bb0230","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1097\/01.jcp.0000142282.62336.e9","article-title":"Atypical antipsychotics and metabolic dysregulation: evaluating the risk\/benefit equation and improving the standard of care","volume":"24","author":"Nasrallah","year":"2004","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.physbeh.2011.05.033_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-2004-815468","article-title":"Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature","volume":"37","author":"Cohen","year":"2004","journal-title":"Pharmacopsychiatry"},{"issue":"7","key":"10.1016\/j.physbeh.2011.05.033_bb0240","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2165\/00003495-200464070-00003","article-title":"Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications","volume":"64","author":"Melkersson","year":"2004","journal-title":"Drugs"},{"issue":"2\u20133","key":"10.1016\/j.physbeh.2011.05.033_bb0245","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr Res"},{"issue":"10","key":"10.1016\/j.physbeh.2011.05.033_bb0250","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.4088\/JCP.v68n1006","article-title":"Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo","volume":"68","author":"L'Italien","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.physbeh.2011.05.033_bb0255","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.diabet.2007.01.003","article-title":"Abnormal glucose metabolism in patients treated with antipsychotics","volume":"33","author":"Scheen","year":"2007","journal-title":"Diabetes Metab"},{"issue":"3","key":"10.1016\/j.physbeh.2011.05.033_bb0260","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4088\/JCP.v69n0320","article-title":"Major changes in glucose metabolism, including new-onset diabetes, within 3months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder","volume":"69","author":"van Winkel","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.physbeh.2011.05.033_bb0265","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s00213-006-0384-5","article-title":"Effects of typical and atypical antipsychotics on glucose\u2013insulin homeostasis and lipid metabolism in first-episode schizophrenia","volume":"186","author":"Wu","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"10.1016\/j.physbeh.2011.05.033_bb0270","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1176\/appi.ajp.160.2.290","article-title":"Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics","volume":"160","author":"Lindenmayer","year":"2003","journal-title":"Am J Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.physbeh.2011.05.033_bb0275","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.schres.2008.01.004","article-title":"Metabolic syndrome in first episode schizophrenia \u2014 a randomized double-blind controlled, short-term prospective study","volume":"101","author":"Saddichha","year":"2008","journal-title":"Schizophr Res"},{"issue":"Suppl. 18","key":"10.1016\/j.physbeh.2011.05.033_bb0280","first-page":"36","article-title":"Abnormalities of glucose metabolism associated with atypical antipsychotic drugs","volume":"65","author":"Newcomer","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.physbeh.2011.05.033_bb0285","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1176\/appi.ajp.160.2.290","article-title":"Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics","volume":"160","author":"Lindenmayer","year":"2003","journal-title":"Am J Psychiatry"},{"issue":"12","key":"10.1016\/j.physbeh.2011.05.033_bb0290","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.4088\/JCP.v64n1206","article-title":"Olanzapine induces insulin resistance: results from a prospective study","volume":"64","author":"Ebenbichler","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.physbeh.2011.05.033_bb0295","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archpsyc.62.1.19","article-title":"Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis","volume":"62","author":"Henderson","year":"2005","journal-title":"Arch Gen Psychiatry"},{"issue":"12","key":"10.1016\/j.physbeh.2011.05.033_bb0300","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1038\/sj.npp.1301392","article-title":"Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients","volume":"32","author":"Haupt","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.physbeh.2011.05.033_bb0305","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1210\/jc.2007-1167","article-title":"Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism","volume":"93","author":"van Nimwegen","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.physbeh.2011.05.033_bb0310","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4088\/JCP.v62n0204","article-title":"Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia","volume":"62","author":"Kinon","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.physbeh.2011.05.033_bb0315","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1055\/s-2002-36391","article-title":"Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives","volume":"35","author":"Baptista","year":"2002","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"10.1016\/j.physbeh.2011.05.033_bb0320","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1210\/jcem.87.6.8599","article-title":"Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo","volume":"87","author":"Sowell","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.physbeh.2011.05.033_bb0325","doi-asserted-by":"crossref","first-page":"5875","DOI":"10.1210\/jc.2002-021884","article-title":"Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp","volume":"88","author":"Sowell","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.physbeh.2011.05.033_bb0330","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2337\/dc06-1063","article-title":"Acute insulin response and beta-cell compensation in normal subjects treated with olanzapine or risperidone for 2weeks","volume":"30","author":"Hardy","year":"2007","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.physbeh.2011.05.033_bb0335","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/sj.npp.1301541","article-title":"Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers","volume":"33","author":"Sacher","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.physbeh.2011.05.033_bb0340","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1210\/jc.2008-1815","article-title":"Effects of olanzapine and haloperidol on the metabolic status of healthy men","volume":"95","author":"Vidarsdottir","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.physbeh.2011.05.033_bb0345","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/01.jcp.0000237947.80764.d9","article-title":"The early effect of olanzapine and risperidone on insulin secretion in atypical-naive schizophrenic patients","volume":"26","author":"Chiu","year":"2006","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"10.1016\/j.physbeh.2011.05.033_bb0350","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4088\/JCP.v63n0509","article-title":"A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1year","volume":"63","author":"Meyer","year":"2002","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.physbeh.2011.05.033_bb0355","first-page":"148","article-title":"Atypical antipsychotic therapy and hyperlipidemia: a review","volume":"6","author":"Koro","year":"2005","journal-title":"Essent Psychopharmacol"},{"issue":"10","key":"10.1016\/j.physbeh.2011.05.033_bb0360","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/sj.mp.4002000","article-title":"Metabolomic mapping of atypical antipsychotic effects in schizophrenia","volume":"12","author":"Kaddurah-Daouk","year":"2007","journal-title":"Mol Psychiatry"},{"issue":"5","key":"10.1016\/j.physbeh.2011.05.033_bb0365","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1017\/S1461145708008468","article-title":"Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients","volume":"11","author":"Vik-Mo","year":"2008","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.physbeh.2011.05.033_bb0370","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.pnpbp.2005.06.008","article-title":"At therapeutic concentrations, olanzapine does not affect basal or insulin-stimulated glucose transport in 3T3-L1 adipocytes","volume":"30","author":"Robinson","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"5","key":"10.1016\/j.physbeh.2011.05.033_bb0375","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/JCP.0b013e318184b4c5","article-title":"Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration","volume":"28","author":"Chintoh","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.physbeh.2011.05.033_bb0380","first-page":"1","article-title":"Acute effects of atypical antipsychotics on whole body insulin resistance in rats: implications for adverse metabolic effects","author":"Houseknecht","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"1\u20133","key":"10.1016\/j.physbeh.2011.05.033_bb0385","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.schres.2008.06.006","article-title":"Insulin resistance following continuous, chronic olanzapine treatment: an animal model","volume":"104","author":"Chintoh","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.physbeh.2011.05.033_bb0390","article-title":"Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents","author":"Albaugh","year":"2010","journal-title":"Schizophr Bull"},{"issue":"10","key":"10.1016\/j.physbeh.2011.05.033_bb0395","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.2337\/db10-0449","article-title":"Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance","volume":"59","author":"Martins","year":"2010","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.physbeh.2011.05.033_bb0400","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1345\/aph.17215","article-title":"Atypical antipsychotics. Part I: pharmacology, pharmacokinetics, and efficacy","volume":"33","author":"Markowitz","year":"1999","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.physbeh.2011.05.033_bb0405","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"HI-Histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/j.physbeh.2011.05.033_bb0410","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.pnpbp.2003.09.008","article-title":"Muscarinic mechanisms of antipsychotic atypicality","volume":"27","author":"Bymaster","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"10.1016\/j.physbeh.2011.05.033_bb0415","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.mp.4002066","article-title":"Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles","volume":"13","author":"Nasrallah","year":"2008","journal-title":"Mol Psychiatry"},{"issue":"9","key":"10.1016\/j.physbeh.2011.05.033_bb0420","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1073\/pnas.0611417104","article-title":"From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase","volume":"104","author":"Kim","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.physbeh.2011.05.033_bb0425","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eurpsy.2009.01.001","article-title":"How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins","volume":"24","author":"Starrenburg","year":"2009","journal-title":"Eur Psychiatry"},{"issue":"3","key":"10.1016\/j.physbeh.2011.05.033_bb0430","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1600-0447.2008.01334.x","article-title":"Which comes first: atypical antipsychotic treatment or cardiometabolic risk?","volume":"119","author":"Stahl","year":"2009","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.physbeh.2011.05.033_bb0435","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1146\/annurev.neuro.30.051606.094324","article-title":"Neurobiology of feeding and energy expenditure","volume":"30","author":"Gao","year":"2007","journal-title":"Annu Rev Neurosci"},{"issue":"2","key":"10.1016\/j.physbeh.2011.05.033_bb0440","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1677\/joe.1.05866","article-title":"Appetite control","volume":"184","author":"Wynne","year":"2005","journal-title":"J Endocrinol"},{"key":"10.1016\/j.physbeh.2011.05.033_bb0445","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.physiol.70.120806.095256","article-title":"The integrative role of CNS fuel-sensing mechanisms in energy balance and glucose regulation","volume":"70","author":"Sandoval","year":"2008","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.physbeh.2011.05.033_bb0450","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1146\/annurev.psych.59.103006.093551","article-title":"The brain, appetite, and obesity","volume":"59","author":"Berthoud","year":"2008","journal-title":"Annu Rev Psychol"},{"issue":"3","key":"10.1016\/j.physbeh.2011.05.033_bb0455","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3945\/jn.108.097618","article-title":"Homeostatic and hedonic signals interact in the regulation of food intake","volume":"139","author":"Lutter","year":"2009","journal-title":"J Nutr"},{"issue":"6","key":"10.1016\/j.physbeh.2011.05.033_bb0460","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.neuron.2006.08.023","article-title":"Leptin receptor signaling in midbrain dopamine neurons regulates feeding","volume":"51","author":"Hommel","year":"2006","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.physbeh.2011.05.033_bb0465","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.appet.2007.05.004","article-title":"Immediate effects of chocolate on experimentally induced mood states","volume":"49","author":"Macht","year":"2007","journal-title":"Appetite"},{"issue":"1","key":"10.1016\/j.physbeh.2011.05.033_bb0470","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejphar.2011.01.034","article-title":"Neurobiology of overeating and obesity: the role of melanocortins and beyond","volume":"660","author":"Pandit","year":"2011","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"10.1016\/j.physbeh.2011.05.033_bb0475","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/mds.20757","article-title":"Compulsive eating and weight gain related to dopamine agonist use","volume":"21","author":"Nirenberg","year":"2006","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.physbeh.2011.05.033_bb0480","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.neuron.2009.01.031","article-title":"Personality, addiction, dopamine: insights from Parkinson's disease","volume":"61","author":"Dagher","year":"2009","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.physbeh.2011.05.033_bb0485","first-page":"81","article-title":"Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case\u2013control study","volume":"33","author":"Cornelius","year":"2010","journal-title":"Sleep"},{"issue":"34","key":"10.1016\/j.physbeh.2011.05.033_bb0490","doi-asserted-by":"crossref","first-page":"10827","DOI":"10.1523\/JNEUROSCI.23-34-10827.2003","article-title":"Reward without dopamine","volume":"23","author":"Cannon","year":"2003","journal-title":"J Neurosci"},{"issue":"3","key":"10.1016\/j.physbeh.2011.05.033_bb0495","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1152\/physrev.00043.2007","article-title":"Histamine in the nervous system","volume":"88","author":"Haas","year":"2008","journal-title":"Physiol Rev"},{"issue":"2","key":"10.1016\/j.physbeh.2011.05.033_bb0500","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/0006-8993(90)91240-H","article-title":"Three histamine receptors (H1, H2 and H3) visualized in the brain of human and non-human primates","volume":"526","author":"Martinez-Mir","year":"1990","journal-title":"Brain Res"},{"issue":"3","key":"10.1016\/j.physbeh.2011.05.033_bb0505","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0026-895X(24)12231-6","article-title":"Discovery of a novel member of the histamine receptor family","volume":"59","author":"Nguyen","year":"2001","journal-title":"Mol Pharmacol"},{"issue":"8","key":"10.1016\/j.physbeh.2011.05.033_bb0510","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1073\/pnas.81.8.2572","article-title":"Histamine-containing neurons in the rat hypothalamus","volume":"81","author":"Panula","year":"1984","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.physbeh.2011.05.033_bb0515","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.pneurobio.2010.07.002","article-title":"Involvement of the brain histaminergic system in addiction and addiction-related behaviors: a comprehensive review with emphasis on the potential therapeutic use of histaminergic compounds in drug dependence","volume":"92","author":"Brabant","year":"2010","journal-title":"Prog Neurobiol"},{"issue":"9","key":"10.1016\/j.physbeh.2011.05.033_bb0520","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.nut.2008.06.014","article-title":"Hypothalamic neuronal histamine regulates body weight through the modulation of diurnal feeding rhythm","volume":"24","author":"Yoshimatsu","year":"2008","journal-title":"Nutrition"},{"issue":"1\u20132","key":"10.1016\/j.physbeh.2011.05.033_bb0525","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0006-8993(98)00186-3","article-title":"Effects of intracerebroventricularly infused histamine and selective H1, H2 and H3 agonists on food and water intake and urine flow in Wistar rats","volume":"793","author":"Lecklin","year":"1998","journal-title":"Brain Res"},{"issue":"9","key":"10.1016\/j.physbeh.2011.05.033_bb0530","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.2337\/diabetes.53.9.2250","article-title":"Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity","volume":"53","author":"Masaki","year":"2004","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.physbeh.2011.05.033_bb0535","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0091-3057(88)90315-2","article-title":"Antihistaminic drugs increase feeding, while histidine suppresses feeding in rats","volume":"31","author":"Orthen-Gambill","year":"1988","journal-title":"Pharmacol Biochem Behav"},{"issue":"1\u20132","key":"10.1016\/j.physbeh.2011.05.033_bb0540","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0006-8993(88)91423-0","article-title":"Blockade of the histamine H1-receptor in the rat ventromedial hypothalamus and feeding elicitation","volume":"441","author":"Sakata","year":"1988","journal-title":"Brain Res"},{"issue":"5","key":"10.1016\/j.physbeh.2011.05.033_bb0545","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.tips.2006.03.008","article-title":"The hypothalamic H1 receptor: a novel therapeutic target for disrupting diurnal feeding rhythm and obesity","volume":"27","author":"Masaki","year":"2006","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"10.1016\/j.physbeh.2011.05.033_bb0550","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/153537020222700309","article-title":"Hypothalamic histamine neurons activate lipolysis in rat adipose tissue","volume":"227","author":"Tsuda","year":"2002","journal-title":"Exp Biol Med (Maywood)"},{"issue":"2","key":"10.1016\/j.physbeh.2011.05.033_bb0555","doi-asserted-by":"crossref","first-page":"376","DOI":"10.2337\/diabetes.50.2.376","article-title":"Central infusion of histamine reduces fat accumulation and upregulates UCP family in leptin-resistant obese mice","volume":"50","author":"Masaki","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.physbeh.2011.05.033_bb0560","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1210\/endo-125-5-2400","article-title":"Cholinergic agonists prime the B-cell to glucose stimulation","volume":"125","author":"Zawalich","year":"1989","journal-title":"Endocrinology"},{"key":"10.1016\/j.physbeh.2011.05.033_bb0565","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1210\/endo-126-1-253","article-title":"Chronic in vivo hyperglycemia impairs phosphoinositide hydrolysis and insulin release in isolated perfused rat islets","volume":"126","author":"Zawalich","year":"1990","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.physbeh.2011.05.033_bb0570","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s004240050174","article-title":"Time-dependent effects of cholinergic stimulation on beta cell responsiveness","volume":"432","author":"Zawalich","year":"1996","journal-title":"Pflugers Arch"},{"issue":"3","key":"10.1016\/j.physbeh.2011.05.033_bb0575","doi-asserted-by":"crossref","first-page":"E525","DOI":"10.1152\/ajpendo.00579.2005","article-title":"Cholinergic regulation of fuel-induced hormone secretion and respiration of SUR1\u2212\/\u2212 mouse islets","volume":"291","author":"Doliba","year":"2006","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.physbeh.2011.05.033_bb0580","doi-asserted-by":"crossref","first-page":"E834","DOI":"10.1152\/ajpendo.00292.2003","article-title":"Restitution of defective glucose-stimulated insulin release of sulfonylurea type 1 receptor knockout mice by acetylcholine","volume":"286","author":"Doliba","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.physbeh.2011.05.033_bb0585","doi-asserted-by":"crossref","first-page":"E475","DOI":"10.1152\/ajpendo.00072.2010","article-title":"Palmitic acid acutely inhibits acetylcholine- but not GLP-1-stimulated insulin secretion in mouse pancreatic islets","volume":"299","author":"Doliba","year":"2010","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.physbeh.2011.05.033_bb0590","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.2337\/diabetes.54.5.1552","article-title":"Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia","volume":"54","author":"Johnson","year":"2005","journal-title":"Diabetes"},{"issue":"24","key":"10.1016\/j.physbeh.2011.05.033_bb0595","first-page":"E430","article-title":"Cephalic phase insulin release in normal weight males: verification and reliability","volume":"261","author":"Teff","year":"1991","journal-title":"Am J Physiol"},{"key":"10.1016\/j.physbeh.2011.05.033_bb0600","series-title":"Appetite and body weight regulation: sugar, fat and macronutrient substitutes","first-page":"37","article-title":"Cephalic phase insulin release in humans: mechanism and function","author":"Teff","year":"1994"},{"key":"10.1016\/j.physbeh.2011.05.033_bb0605","first-page":"R1371","article-title":"Oral sensory stimulation improves glucose tolerance: effects on post-prandial glucose, insulin, C-peptide and glucagon","volume":"270","author":"Teff","year":"1996","journal-title":"Am J Physiol"},{"key":"10.1016\/j.physbeh.2011.05.033_bb0610","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1210\/jc.2003-032094","article-title":"Prolonged mild hyperglycemia induces vagally mediated compensatory increase in C-peptide secretion in humans","volume":"89","author":"Teff","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.physbeh.2011.05.033_bb0615","first-page":"772","article-title":"The effect of atropine on the insulin release caused by oral and intravenous glucose in human subjects","volume":"83","author":"Henderson","year":"1976","journal-title":"Acta Endocrinol"},{"key":"10.1016\/j.physbeh.2011.05.033_bb0620","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/0304-4165(71)90089-4","article-title":"Regulation of glycogen metabolism in liver by the autonomic nervous system vs activation of glycogen synthetase by vagal stimulation","volume":"252","author":"Shimazu","year":"1971","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.physbeh.2011.05.033_bb0625","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1126\/science.156.3779.1256","article-title":"Glycogen synthetase activity in liver: regulation by the autonomic nerves","volume":"156","author":"Shimazu","year":"1967","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.physbeh.2011.05.033_bb0630","doi-asserted-by":"crossref","first-page":"E544","DOI":"10.1152\/ajpendo.2000.278.3.E544","article-title":"Combined intraportal infusion of acetylcholine and adrenergic blockers augments net hepatic glucose uptake","volume":"278","author":"Shiota","year":"2000","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.physbeh.2011.05.033_bb0635","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0014-5793(97)00254-8","article-title":"Sensing by intrahepatic muscarinic nerves of a portal\u2013arterial glucose concentration gradient as a signal for insulin-dependent glucose uptake in the perfused rat liver","volume":"406","author":"Stumpel","year":"1997","journal-title":"FEBS Lett"},{"key":"10.1016\/j.physbeh.2011.05.033_bb0640","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1172\/JCI112073","article-title":"Effects of atropine and gastric inhibitory polypeptide on hepatic glucose uptake and insulin extraction in conscious dogs","volume":"76","author":"Chap","year":"1985","journal-title":"J Clin Invest"},{"key":"10.1016\/j.physbeh.2011.05.033_bb0645","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cmet.2004.11.001","article-title":"A brain\u2013liver circuit regulates glucose homeostasis","volume":"1","author":"Pocai","year":"2005","journal-title":"Cell Metab"},{"key":"10.1016\/j.physbeh.2011.05.033_bb0650","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1172\/JCI113617","article-title":"Direct muscarinic cholinergic inhibition of hepatic glucose production in humans","volume":"82","author":"Boyle","year":"1988","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.physbeh.2011.05.033_bb0655","first-page":"S2541","article-title":"Short-term administration of olanzapine induces insulin resistance in healthy subjects, independent of weight gain","volume":"31","author":"Teff","year":"2010","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.physbeh.2011.05.033_bb0660","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1530\/EJE-09-0433","article-title":"Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets","volume":"162","author":"Vidarsdottir","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.physbeh.2011.05.033_bb0665","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.neuron.2006.08.023","article-title":"Leptin receptor signaling in midbrain dopamine neurons regulates feeding","volume":"51","author":"Hommel","year":"2006","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.physbeh.2011.05.033_bb0670","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.appet.2006.05.016","article-title":"From motivation to behaviour: a model of reward sensitivity, overeating, and food preferences in the risk profile for obesity","volume":"48","author":"Davis","year":"2007","journal-title":"Appetite"},{"issue":"4","key":"10.1016\/j.physbeh.2011.05.033_bb0675","first-page":"R882","article-title":"Adiposity signals and food reward: expanding the CNS roles of insulin and leptin","volume":"284","author":"Figlewicz","year":"2003","journal-title":"Am J Physiol"},{"issue":"12B","key":"10.1016\/j.physbeh.2011.05.033_bb0680","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/0028-3908(84)90098-4","article-title":"Serotonin and appetite","volume":"23","author":"Blundell","year":"1984","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.physbeh.2011.05.033_bb0685","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0195-6663(86)80056-3","article-title":"Peripheral and central mechanisms of action of serotoninergic anorectic drugs","volume":"7","author":"Carrub","year":"1986","journal-title":"Appetite"},{"key":"10.1016\/j.physbeh.2011.05.033_bb0690","first-page":"237","article-title":"Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity","volume":"15","author":"Piji","year":"1991","journal-title":"Int J Obes"}],"container-title":["Physiology & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031938411003027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031938411003027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:57:10Z","timestamp":1758477430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031938411003027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":138,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0031938411003027"],"URL":"https:\/\/doi.org\/10.1016\/j.physbeh.2011.05.033","relation":{},"ISSN":["0031-9384"],"issn-type":[{"value":"0031-9384","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism","name":"articletitle","label":"Article Title"},{"value":"Physiology & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.physbeh.2011.05.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}